Beyond pancreatic cancer: Irinotecan and gemcitabine in solid tumors and hematologic malignancies

Caio Max S. Rocha Lima, James J. Urbanic, Asheesh Lal, Rayna Kneuper-Hall, Chris Y. Brunson, Mark R. Green

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Non-platinum combinations including gemcitabine and irinotecan (Gemzar; Eli Lilly and Company, Indianapolis, IN) for the management of a variety of malignancies have started to emerge. Gemcitabine and irinotecan are well-tolerated single agents, each with a broad spectrum of antitumor activity. Preclinical data suggests synergy for the two drugs when used in combination. A phase I trial has defined a well-tolerated combination regimen using both drugs on a day-1, -8 schedule every 3 weeks. Phase II data suggest activity for the combination in pancreatic cancer, and a phase III trial of the two-drug combination versus gemcitabine alone is underway in previously untreated pancreatic cancer patients. Other phase II trials evaluating the impact of this combination on a variety of other tumors, such as non-small cell lung, small cell lung, breast, colorectal, and non-Hodgkin's lymphoma, are either forthcoming or in progress.

Original languageEnglish (US)
Pages (from-to)34-43
Number of pages10
JournalSeminars in Oncology
Volume28
DOIs
StatePublished - Jun 2001

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Beyond pancreatic cancer: Irinotecan and gemcitabine in solid tumors and hematologic malignancies'. Together they form a unique fingerprint.

  • Cite this

    Rocha Lima, C. M. S., Urbanic, J. J., Lal, A., Kneuper-Hall, R., Brunson, C. Y., & Green, M. R. (2001). Beyond pancreatic cancer: Irinotecan and gemcitabine in solid tumors and hematologic malignancies. Seminars in Oncology, 28, 34-43. https://doi.org/10.1016/S0093-7754(01)80007-5